TABLE 31

Hepatocyte steatosis (Fatty change) Incidence and Histology Scores in ob/ob mice

	Vehicle	PEG-Cmpd 2 (8.14 nmol/kg)	Cmpd 170 (8.14 nmol/kg)	PEG-Cmpd 2 (81.45 nmol/kg)	Cmpd 170 (81.45 nmol/kg
			No.		
Score	6	6	6	6	6
0	—	—	1	6	6
1	—	6	5	—	—
2	6	—	—	—	—

TABLE 32

Perisinusoidal Lipid-laden Cell Incidence and Histology Scores in ob/ob mice.

	Vehicle	PEG-Cmpd 2 (8.14 nmol/kg)	Cmpd 170 (8.14 nmol/kg)	PEG-Cmpd 2 (81.45 nmol/kg)	Cmpd 170 (81.45 nmol/kg
			No.		
Score	6	6	6	6	6
0	ND	—	—	1	—
1	ND	—	1	4	1
2	ND	—	—	1	5
3	ND	6	5	—	—

SEQUENCE LISTING

The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US11248031B2). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. A method of treating a disease associated with fibrosis selected from non-alcoholic steatohepatitis (NASH), liver fibrosis, or cirrhosis comprising administering to a patient in need thereof an effective amount of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety having a molecular weight of about 30 kDa, wherein said modified FGF-21 polypeptide is administered by subcutaneous injection.

2. The method of claim **1**, wherein said disease associated with fibrosis is NASH, wherein NASH is treated.

3. The method of claim **1**, wherein said disease associated with fibrosis is cirrhosis.

4. The method of claim **1**, wherein said disease associated with fibrosis is liver fibrosis.

5. The method of claim **1**, which results in one or more of decreased hepatic fat fraction and increased adiponectin levels in said patient.

6. The method of claim **1**, wherein prior to treatment the patient exhibits at least one of a fatty liver index of at least about 60, a hepatic fat fraction percentage of at least 10%, a body mass index greater than or equal to 25 kg/m^2, and/or NASH Clinical Research Network (CRN) fibrosis stage 1-3.

7. The method of claim **6**, wherein said hepatic fat fraction is determined by magnetic resonance imaging and/or said NASH CRN fibrosis stage is determined by a liver biopsy.

8. The method of claim **1**, wherein said modified FGF-21 polypeptide is administered at a frequency of about once per week.

9. The method of claim **1**, wherein said modified FGF-21 polypeptide is administered at a frequency of about once per day, about twice per week, about once per two weeks, or about once per four weeks.

10. The method of claim **1**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 20 mg per week.

11. The method of claim **1**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 40 mg per week.

12. A method of treating NASH in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety having a molecular weight of about 30 kDa, wherein said modified FGF-21 polypeptide is administered by subcutaneous injection.

13. The method of claim **12**, which results in one or more of decreased hepatic fat fraction and increased adiponectin levels in said patient.

14. The method of claim **12**, wherein prior to treatment the patient exhibits at least one of a fatty liver index of at least about 60, a hepatic fat fraction percentage of at least